EIF2AK2 and hepatocellular carcinoma: With this perspective, it would be necessary to consider in the patient’s follow-up greater controls in assessing the state of the liver for longer periods and in particular considering, before starting DAA treatment, the presence of a greater number of ISDR/PKR-bd substitutions as a prognostic marker for advanced fibrosis and HCC.